Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Cost of Revenue (2019 - 2025)

Biodesix (BDSX) has disclosed Cost of Revenue for 7 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 16.85% year-over-year to $11.1 million, compared with a TTM value of $16.7 million through Dec 2025, down 2.57%, and an annual FY2025 reading of $16.7 million, up 7.36% over the prior year.
  • Cost of Revenue was $11.1 million for Q4 2025 at Biodesix, up from $1.7 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $18.2 million in Q1 2021 and bottomed at $1.6 million in Q3 2024.
  • Average Cost of Revenue over 5 years is $4.6 million, with a median of $3.2 million recorded in 2022.
  • Peak annual rise in Cost of Revenue hit 1052.31% in 2021, while the deepest fall reached 82.99% in 2021.
  • Year by year, Cost of Revenue stood at $2.5 million in 2021, then surged by 32.61% to $3.3 million in 2022, then grew by 2.06% to $3.4 million in 2023, then skyrocketed by 182.04% to $9.5 million in 2024, then rose by 16.85% to $11.1 million in 2025.
  • Business Quant data shows Cost of Revenue for BDSX at $11.1 million in Q4 2025, $1.7 million in Q3 2025, and $2.0 million in Q2 2025.